Please assess the completion status of the following clinical trial:

Trial Title: Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed diagnosis of chronic phase CML within last 3 months~* Patients with cytogenetically confirmed Ph positive CML in early chronic phase~Exclusion Criteria:~* Patients with Philadelphia chromosome negative but BCR-ABL positive CML~* Patients who used imatinib for 8 days or longer before study entry~* Patients who had been treated with other targeted anti-cancer therapy, except for Hydrea or Agrylin, which inhibits the growth of leukemic cells~* Patients with impaired cardiac function~* Cytologically confirmed CNS involvement~* Severe or uncontrolled chronic medical condition~* Other significant congenital or acquired bleeding disorders that are not related to underlying leukemia~* Patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: ACTIVE_COMPARATOR): Imatinib 400mg QD
- Radotinib 600mg (Type: EXPERIMENTAL): Radotinib 300mg BID
- Radotinib 800mg (Type: EXPERIMENTAL): Radotinib 400mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).